• Je něco špatně v tomto záznamu ?

Long-term, continuous, subcutaneous levodopa/carbidopa infusion with ND0612 in Parkinson's disease: 3-year outcomes from the open-label BeyoND study

AL. Ellenbogen, W. Poewe, AJ. Espay, T. Simuni, T. Gurevich, T. Yardeni, N. Lopes, N. Sasson, R. Case, F. Stocchi, BeyoND study group

. 2025 ; 132 (-) : 107293. [pub] 20250116

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25009659

INTRODUCTION: ND0612 is being investigated as a continuous, subcutaneous levodopa/carbidopa infusion, in combination with oral levodopa/carbidopa, for motor fluctuations in Parkinson's disease (PD). One-year data from the ongoing BeyoND study (NCT02726386) showed that the ND0612 regimen was safe and well tolerated and provided a sustained ≥2-h improvement in daily Good ON-time through 12 months of treatment. METHODS: We describe 3-year safety and efficacy outcomes for participants who completed 12 months of ND0612 treatment in the core study period and entered the extension phase. RESULTS: Of the 214 enrolled participants, 120 completed the core 1-year period, and 114 participants continued into the extension phase. Of these, 95/114 (83.3 %) completed 2 years and 77/114 (67.5 %) completed 3 years of study treatment. Key reasons for discontinuation were treatment-emergent adverse events (TEAEs) (n = 5 and n = 11 after 2 and 3 years, respectively) and withdrawal of consent (n = 9 and n = 5, respectively). TEAEs were reported by 105/114 (92.1 %) participants in Year 1, 77/114 (67.5 %) in Year 2, and 73/95 (76.8 %) in Year 3. While most participants experienced infusion site reactions, these led to discontinuation in only five participants during this extension. At Month 36, the mean reduction in OFF-time from baseline was 2.81 h and the increase in Good ON-time was 2.79 h. CONCLUSIONS: Three-year results from this open-label study support the long-term safety, tolerability, and efficacy of ND0612. For participants who entered the extension phase, the high rate of retention supports a favorable benefit-risk ratio of the ND0612 regimen for patients with PD experiencing motor fluctuations.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009659
003      
CZ-PrNML
005      
20250429134906.0
007      
ta
008      
250415e20250116enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.parkreldis.2025.107293 $2 doi
035    __
$a (PubMed)39884033
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Ellenbogen, Aaron L $u Michigan Institute for Neurological Disorders, Farmington Hills, MI, USA. Electronic address: aaron@questri.com
245    10
$a Long-term, continuous, subcutaneous levodopa/carbidopa infusion with ND0612 in Parkinson's disease: 3-year outcomes from the open-label BeyoND study / $c AL. Ellenbogen, W. Poewe, AJ. Espay, T. Simuni, T. Gurevich, T. Yardeni, N. Lopes, N. Sasson, R. Case, F. Stocchi, BeyoND study group
520    9_
$a INTRODUCTION: ND0612 is being investigated as a continuous, subcutaneous levodopa/carbidopa infusion, in combination with oral levodopa/carbidopa, for motor fluctuations in Parkinson's disease (PD). One-year data from the ongoing BeyoND study (NCT02726386) showed that the ND0612 regimen was safe and well tolerated and provided a sustained ≥2-h improvement in daily Good ON-time through 12 months of treatment. METHODS: We describe 3-year safety and efficacy outcomes for participants who completed 12 months of ND0612 treatment in the core study period and entered the extension phase. RESULTS: Of the 214 enrolled participants, 120 completed the core 1-year period, and 114 participants continued into the extension phase. Of these, 95/114 (83.3 %) completed 2 years and 77/114 (67.5 %) completed 3 years of study treatment. Key reasons for discontinuation were treatment-emergent adverse events (TEAEs) (n = 5 and n = 11 after 2 and 3 years, respectively) and withdrawal of consent (n = 9 and n = 5, respectively). TEAEs were reported by 105/114 (92.1 %) participants in Year 1, 77/114 (67.5 %) in Year 2, and 73/95 (76.8 %) in Year 3. While most participants experienced infusion site reactions, these led to discontinuation in only five participants during this extension. At Month 36, the mean reduction in OFF-time from baseline was 2.81 h and the increase in Good ON-time was 2.79 h. CONCLUSIONS: Three-year results from this open-label study support the long-term safety, tolerability, and efficacy of ND0612. For participants who entered the extension phase, the high rate of retention supports a favorable benefit-risk ratio of the ND0612 regimen for patients with PD experiencing motor fluctuations.
650    _2
$a lidé $7 D006801
650    12
$a Parkinsonova nemoc $x farmakoterapie $7 D010300
650    12
$a levodopa $x aplikace a dávkování $x škodlivé účinky $7 D007980
650    12
$a karbidopa $x aplikace a dávkování $7 D002230
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a senioři $7 D000368
650    12
$a fixní kombinace léků $7 D004338
650    _2
$a lidé středního věku $7 D008875
650    12
$a antiparkinsonika $x aplikace a dávkování $x škodlivé účinky $7 D000978
650    12
$a subkutánní infuze $7 D055104
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Poewe, Werner $u Department of Neurology, Medical University Innsbruck, Innsbruck, Austria
700    1_
$a Espay, Alberto J $u James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, University of Cincinnati, Cincinnati, OH, USA
700    1_
$a Simuni, Tanya $u Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
700    1_
$a Gurevich, Tanya $u Movement Disorders Unit, Neurological Institute, Tel Aviv Medical Centre, Faculty of Medicine, Sagol School of Neurosciences, Tel Aviv University, Tel Aviv, Israel
700    1_
$a Yardeni, Tami $u NeuroDerm Ltd., Rehovot, Israel
700    1_
$a Lopes, Nelson $u NeuroDerm Ltd., Rehovot, Israel
700    1_
$a Sasson, Nissim $u NeuroDerm Ltd., Rehovot, Israel
700    1_
$a Case, Ryan $u Mitsubishi Tanabe Pharma America, Inc., Jersey City, NJ, USA
700    1_
$a Stocchi, Fabrizio $u University San Raffaele Roma and Institute for Research and Medical Care IRCCS San Raffaele, Roma, Italy
710    2_
$a BeyoND study group
773    0_
$w MED00006198 $t Parkinsonism & related disorders $x 1873-5126 $g Roč. 132 (20250116), s. 107293
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39884033 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134902 $b ABA008
999    __
$a ok $b bmc $g 2311183 $s 1246740
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 132 $c - $d 107293 $e 20250116 $i 1873-5126 $m Parkinsonism & related disorders $n Parkinsonism Relat Disord $x MED00006198
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...